biospecimen banks

CPDR Integrated Biomedical Informatics Platform

Developing Effective Prevention, Diagnostic and Treatment Strategies

The infrastructure of Integrated Biomedical Informatics Platform (IBIP) has been established with business requirement analysis, platform blueprint, implementation strategies, and organization-wide policies, standards on information management and information system development. Program-specific resource informatics systems are also constructed via setting up sophisticated and robust information systems and tools in each research program to streamline the in-house information management by its own requirements. The construction of those systems follows policies, standards and SOPs regulated by the platform. They can be deployed onto IBIP, which:

  • Enable the programmable connection between resource informatics systems and the platform as a network to facilitate data communication, and to implement interoperability
  • Facilitate dynamic and seamless interdisciplinary data integration and annotation via dynamic data binding
  • Provide systematic solution to data quality monitoring and control, data query, data sharing, distribution and version control.
  • Provide comprehensive strategies and solution to information security, human privacy protection and regulatory compliance on data collection, integration, analysis and management
  • Establish policies, standards, and SOPs on organization level and research program level for operation within information system, data management, and information sharing in collaboration
  • Provide professional administration on information system and databases

Patient's privacy protection and data security are two most critical and most challenging factors regarding the research data management. Within IBIP, multiple strategies are applied to ensure the privacy protection and data security.

Privacy protection is ensured by processes of automated data de-identification and centralized patient identification. De-identification enforces the filtering and localized storage of demographic information collected by data management systems. Centralized patient identification will make sure patients consenting to the program are uniquely assigned a random selected identification number, which will serve as the primary patient identification in centralized, de-identified research data pool, and the only linkage between local demographic databases and central research databases.

 

CURRENT EVENTS


WRNMMC UsToo!
Quarterly Guest Speakers


Tschlitz

Dr. Philip Arlen
National Cancer Institute

Topic: "Prostate Cancer: An Overview and Update of Novel Treatment Modalities"
There have been remarkable advances in the therapy for prostate cancer over the past decade. We will be discussing these advances as well as new treatment options in clinical trials.

Date: Thursday 5 May 2016
Time: 1900-2030
Location: Walter Reed National Military Medical Center (America Building, 2nd floor, Room 2525) and Fort Belvoir Community Hospital (via video teleconference in Oaks Pavilion, 1st floor, Room 332).

Read the MAY 2016 WRNMMC UsToo! Newsletter

Go to WRNMMC UsToo! Newsletter Archive

 

February 2, 2016

CPDR Urology Residents Take Top Awards at 2016 James C. Kimbrough Urological Seminar

Urology Residents conducting research at The Center for Prostate Disease Research (CPDR), Department of Surgery, Uniformed Services University of the Health Sciences and the Walter Reed National Military Medical Center presented their research at the Residents Competition category of the James C. Kimbrough Urological Seminar, San Diego, 2016.

Read Full Article

 

January 11, 2016

A Novel Gene Alteration Associates with Aggressive Prostate Cancer in African American Men

The USU, Walter Reed-Bethesda and JPC collaborative team, through comprehensive evaluations of matched cohorts of African American and Caucasian American prostate cancers, previously established a higher frequency of ERG alterations in Caucasians (50-70%) and its significantly lower frequency in African Americans (20-25%). These intriguing observations actually provided the rational for the current study focusing on whole genome evaluations of prostate cancers from these two patient populations.

Read Full Article